ktsimage Investment Overview I last updated on Geron Corporation (NASDAQ:GERN), the Foster City, California-based biotech primarily focused on securing commercial approval in the U.S. for its lead candidate, imetelstat, in the indication of transfusion-dependent anemia in adult patients, with low-to-intermediate-1 risk myelodysplastic syndromes ("MDS"), in a note for Seeking Alpha back in early December last year. I gave the company and its stock a "Buy" rating, based on my belief that the FDA is likely to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-20859 For the transition period from to . GERON CORPORATION (Exact name of registrant as specified in its charter) | Delaware | | 75-2287752 | | --- | --- | --- | | ( ...

Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript February 28, 2024 8:00 AM ET Company Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman and CEO Faye Feller - EVP and CMO Anil Kapur - EVP of Corporate Strategy and CCO Michelle Robertson - EVP and CFO Conference Call Participants Corinne Johnson - Goldman Sachs Kalpit Patel - B. Riley Stephen Willey - Stifel Ethan Markowski - Needham & Company Joel Beatty - Baird Operator Good morning. My name is Rob a ...

*Mutation data were available for 18/21 patients receiving imetelstat with ≥1-year TI LR-MDS: lower-risk myelodysplastic syndromes; TI: transfusion independence; VAF: variant allele frequency Conclusion • With a median TI duration over 2 years, • Elimination of MDSassociated mutations suggests the potential of imetelstat to have disease-modifying activity. ASH 2023: Durable TI Associated with Better Survival Abstract #2440 Conclusion For transfusion dependent patients achievement of TI with second line trea ...

Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Corporate Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman, President and Chief Executive Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer Michelle Robertson - Executive Vice President and Chief Financial Officer Conference Call Participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 75-2287752 (State or other jurisdi ...

Geron Corporation (NASDAQ:GERN) Q2 2023 Results Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman of the Board, President and Chief Executive Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer Olivia Bloom - Executive Vice President, Finance, Chief Financial Officer and Treas ...

OLIVIA BLOOM EVP, Chief Financial Officer Andrew J. Grethlein, Ph.D. EVP, Chief Operating Officer 3 Key Q2 Achievements Drive Geron Toward Potential Launch • Commercial planning on track for launch readiness in early 2024 5 • Expect to submit MAA in EU for LR MDS in Q4 2023 New IMerge Phase 3 Data and Analyses Presented at ASCO and EHA Highly statistically significant (p<0.001) and clinically meaningful increases in mean change in hemoglobin levels over time for imetelstat-treated patients versus placebo In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 75-2287752 (State or other jurisdiction ...

Geron Corporation (NASDAQ:GERN) Q1 2023 Results Conference Call May 11, 2023 10:30 AM ET Company Participants Aron Feingold - VP, IR and Corporate Communications Dr. John Scarlett - Chairman and CEO Olivia Bloom - EVP and CFO Dr. Faye Feller - EVP and CMO Anil Kapur - EVP, Corporate Strategy and Chief Commercial Officer Conference Call Participants Stephen Willey - Stifel Kalpit Patel - B. Riley Joel Beatty - Baird Gil Blum - Needham & Company Corinne Jenkins - Goldman Sachs Operator Good morning. My name i ...